Vaxcyte COO sells shares, exercises stock options
Vaxcyte, Inc. chief operating officer Jim Wassil reported a set of transactions in the company’s common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Vaxcyte, Inc. chief operating officer Jim Wassil reported a set of transactions in the company’s common stock. He sold a total of 2,250 shares in open-market trades at weighted-average prices around the mid‑$50s per share under a Rule 10b5-1 trading plan adopted on December 9, 2025. On the same date, he exercised a stock option to acquire 516 shares at an exercise price of $5.35 per share, reducing his remaining option position. After these trades, he continues to hold a substantial stake of more than 150,000 shares of common stock, along with tens of thousands of remaining stock options.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
5 txns
Insider
Wassil Jim
Role
CHIEF OPERATING OFFICER
Sold
2,250 shs ($127K)
Approx. gross sale proceeds
$127K
Approx. exercise cost
$3K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 516 | $0.00 | $0.00 |
| Exercise | Common Stock | 516 | $5.35 | $3K |
| Sale | Common Stock | 1,788 | $56.03 | $100K |
| Sale | Common Stock | 456 | $57.473 | $26K |
| Sale | Common Stock | 6 | $57.82 | $346.92 |
Holdings After Transaction:
Stock Option (right to buy) — 71,148 contracts (Direct);
Common Stock — 156,760 shares (Direct)
Footnotes (4)
- F1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.
- F2. The price reported is a weighted-average price. The shares were sold at prices ranging from $55.60 to $56.595. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3. The price reported is a weighted-average price. The shares were sold at prices ranging from $56.695 to $57.59. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4. Stock Option is fully vested and exercisable.
Key Figures
Shares sold: 2,250 shares
Sale price range: $55.60–$57.59 per share
Options exercised: 516 shares
+4 more
7 metrics
Shares sold
2,250 shares
Total common stock sold in open-market transactions on July 1, 2026
Sale price range
$55.60–$57.59 per share
Weighted-average sales with trades within these price bands
Options exercised
516 shares
Common stock acquired via option exercise on July 1, 2026
Option exercise price
$5.35 per share
Exercise price for stock option (right to buy) converted
Options remaining
71,148 options
Stock options outstanding after the reported option exercise
Post-transaction common shares
>150,000 shares
Approximate remaining common stock holdings after trades
Rule 10b5-1 plan adoption date
December 9, 2025
Pre-arranged trading plan governing the reported sales
Key Terms
Rule 10b5-1 trading plan, weighted-average price, Stock Option (right to buy), derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted-average price financial
"The price reported is a weighted-average price. The shares were sold at prices ranging from $55.60 to $56.595."
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
Stock Option (right to buy) financial
"Stock Option (right to buy) with underlying security title Common Stock."
derivative security financial
"Exercise or conversion of derivative security described for the option transaction."
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"Transaction action listed as open-market sale for common stock transactions."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Vaxcyte (PCVX) COO Jim Wassil report?
Vaxcyte COO Jim Wassil reported selling 2,250 shares of common stock and exercising options for 516 shares. All transactions occurred on July 1, 2026, and involved open-market sales and an option exercise disclosed in a Form 4 filing.
Were the Vaxcyte (PCVX) insider sales under a Rule 10b5-1 plan?
Yes. The filing states the reported sales were effected under a Rule 10b5-1 trading plan adopted on December 9, 2025. Such pre-arranged plans automate trading and can indicate the timing was set in advance, rather than based on new information.
What stock options did the Vaxcyte (PCVX) COO exercise in this Form 4?
He exercised a stock option covering 516 shares of Vaxcyte common stock at an exercise price of $5.35 per share. The option is described as fully vested and exercisable, and the transaction converts derivative rights into actual common shares.
What remaining Vaxcyte (PCVX) stock option position is shown in the Form 4?
After the exercise of 516 options, the derivative table lists 71,148 stock options outstanding. These options relate to Vaxcyte common stock, carry a $5.35 exercise price, and have an expiration date of April 17, 2030, according to the filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates